Late-stage oral therapy designed to reduce bacterial exacerbations, hospital admissions and the healthcare burden of COPD Melbourne, Australia; New York, USA; and London, UK – XX June 2026 – Respien Pty Ltd (“Respien”), an Australian biopharmaceutical company developing novel respiratory therapies, has appointed Sage Healthcare Ltd and The Sage Group Inc. (collectively “Sage”) to lead a global partnering process for HI-164, Respien’s lead Phase 3-ready respiratory asset. HI-1